Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P240040/S002

Oncomine Dx Express Test

Life Technologies Corporation · Decision date Oct 15, 2025

FDA DECISIONP240040/S002

What did the FDA approve?

FDA records P240040/S002 as a supplement to PMA P240040, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Oct 15, 2025.

FDA approval order statement

Approval of the non-clinical Post-Approval Study (PAS) protocol for precision and sample equivalency studies using core needle biopsy and fine needle aspirate samples (PCP0141593).
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track No User Fee
Clinical specialty
Pathology
Decision date
Oct 15, 2025
FDA change category
Postapproval Study Protocol

FDA source record

Regulatory record facts

Identifier
P240040/S002
Regulatory pathway
PMA supplement
Product code
PQP
Decision code
APPR
Decision date
Oct 15, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Next generation sequencing oncology panel, somatic or germline variant detection system.

Product code
PQP
FDA device class
3

For the original device and its historical approval scope, see PMA P240040. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P240040 · Original PMA

    Oncomine Dx Express Test

  2. P240040/S002 received

    Application receipt date recorded by FDA.

  3. P240040/S001 · Related supplement

    Oncomine Dx Express Test

  4. P240040/S002 · FDA decision

    Normal 180 Day Track No User Fee

  5. P240040/S003 · Related supplement

    Oncomine Dx Express Test

  6. P240040/S006 · Related supplement

    Oncomine Dx Express Test

  7. P240040/S005 · Related supplement

    Oncomine Dx Express Test

  8. P240040/S008 · Related supplement

    Oncomine Dx Express Test

Timeline entries are records held by MedtechLedger for P240040. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P240040

Product / regulatory recordCompanyPathwayDecision dateSource
Life Technologies CorporationPMA approvalJul 2, 2025FDA
Life Technologies CorporationPMA supplementAug 7, 2025FDA
Life Technologies CorporationPMA supplementOct 22, 2025FDA
Life Technologies CorporationPMA supplementJun 8, 2026FDA
Life Technologies CorporationPMA supplementSep 9, 2026FDA
Life Technologies CorporationPMA supplementNov 4, 2026FDA

Explore the linked device profile

Other records with product code PQP

Product / regulatory recordCompanyPathwayDecision dateSource
xT CDxP210011/S006
Tempus AI, Inc.PMA supplementOct 23, 2026FDA
MI Cancer SeekP240010/S007
Caris Life SciencesPMA supplementOct 16, 2026FDA
Foundation Medicine, Inc.PMA supplementSep 18, 2026FDA
Guardant360 CDxP200010/S029
Guardant Health, Inc.PMA supplementSep 18, 2026FDA
FoundationOne CDxP170019/S069
Foundation Medicine, Inc.PMA supplementSep 16, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Life Technologies Corporation

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
7335 Executive Way, Frederick, MD, 21704

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records